Although two studies from Spain and the U.S. also showed lower pSUVmax in EGFR mutant NSCLC patients than that in EGFR wild-type patients [11, 12], it is still necessary to note the potential difference between different regions and races. This evidence concerns the gene EGFR and non-small cell lung carcinoma.